NYSE: AVNSAvanos Medical Inc Stock
$15.81+0.01 (+0.06%)
Updated Jan 24, 2025
AVNS Price
$15.81
Fair Value Price
N/A
Market Cap
$726.58M
52 Week Low
$14.98
52 Week High
$25.36
P/E
45.17x
P/B
0.59x
P/S
1.62x
PEG
0.37x
Dividend Yield
N/A
Revenue
$681.50M
Earnings
$15.70M
Gross Margin
55.5%
Operating Margin
4.81%
Profit Margin
2.3%
Debt to Equity
0.35
Operating Cash Flow
$56M
Beta
1.09
Next Earnings
Feb 18, 2025
Ex-Dividend
N/A
Next Dividend
N/A
AVNS Overview
Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. Its product portfolio includes digestive health products, including enteral feeding tubes and solutions; respiratory health products, such as closed airway suction systems and oral care kits; and acute pain products comprising surgical pain pumps, and cold and compression therapy systems, as well as interventional pain management solutions that include minimally invasive interventional pain therapies. The company sells its products under the MIC-KEY, CORPAK, NEOMED, BALLARD, MICROCUFF, ENDOCLEAR, ON-Q, AMBIT, GAME READY, and COOLIEF brand names. It markets its products directly to hospitals and other healthcare providers, and through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AVNS's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
A
Value
A
Growth
C
Momentum
C
Sentiment
B
Safety
C
Financials
B
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
D
AVNS
Ranked#8 of 128
Ranked#8 of 128
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $33.49 | A | |
| $17.39 | A | |
| $7.14 | A |
Be the first to know about important AVNS news, forecast changes, insider trades & much more!
AVNS News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AVNS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AVNS ($15.81) is trading below its intrinsic value of $16.33, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AVNS is poor value based on its earnings relative to its share price (45.17x), compared to the US market average (30.33x)
P/E vs Market Valuation
AVNS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more AVNS due diligence checks available for Premium users.
Valuation
AVNS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
45.17x
Industry
40.61x
Market
30.33x
AVNS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
AVNS is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
AVNS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.59x
Industry
4.3x
AVNS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AVNS price to earnings growth (PEG)
For valuing profitable companies with growth potential
AVNS is good value based... subscribe to Premium to read more.
PEG Value Valuation
AVNS's financial health
Profit margin
Revenue
$170.4M
Net Income
$4.3M
Profit Margin
2.5%
AVNS's Earnings (EBIT) of $32.80M... subscribe to Premium to read more.
Interest Coverage Financials
AVNS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.7B
Liabilities
$426.5M
Debt to equity
0.35
AVNS's short-term assets ($472.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVNS's short-term assets ($472.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVNS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AVNS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$23.0M
Investing
-$12.0M
Financing
-$16.0M
AVNS's operating cash flow ($55.50M)... subscribe to Premium to read more.
Debt Coverage Financials
AVNS vs Medical Device Stocks
Avanos Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.